The Role of MHC Class I and Class II Molecules in Antibacterial Immunity and Treatment of Bacterial Diseases-Reference-Cited by-同舟云学术

The Role of MHC Class I and Class II Molecules in Antibacterial Immunity and Treatment of Bacterial Diseases

Published:2022-11-18 Issue:7-8 Volume:67 Page:71-81
ISSN:0235-2990
Container-title:Antibiotics and Chemotherapy
language:
Short-container-title:A&Ch

Author:

Petrova N. V.¹^ORCID,Emelyanova A. G.¹^ORCID,Kovalchuk A. L.²^ORCID,Tarasov S. A.¹^ORCID

Affiliation:

1. Institute of General Pathology and Pathophysiology; Research and Production Company Materia Medica Holding LLC

2. Research and Production Company Materia Medica Holding LLC

Publisher

Publishing House OKI

Subject

Infectious Diseases,Microbiology (medical),General Medicine,Microbiology

Reference99 articles.

1. Belete T.M. Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents. Hum Microbiome J. 2019; 11: 100052. doi:10.1016/j.humic.2019.01.001.

2. Brown E.D., Wright G.D. Antibacterial drug discovery in the resistance era. Nature. 2016; 529 (7586): 336–343. doi:10.1038/nature17042.

3. World Helath Organization (WHO). 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. 2021. Availible from https://www.who.int/publications/i/item/9789240021303

4. Butler M.S., Paterson D.L. Antibiotics in the clinical pipeline in October 2019. J Antibiot (Tokyo). 2020; 73 (6): 329–364. doi:10.1038/s41429-020-0291-8.

5. Koo H., Allan R.N., Howlin R.P., Stoodley P., Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017; 15 (12): 740–755. doi:10.1038/nrmicro.2017.99.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon gamma as a trigger of chronic viral infections and inflammatory dermatoses;Meditsinskiy sovet = Medical Council;2024-05-11

2. The effect of etiopathogenetic therapy of COVID-19 on the severity of the disease: results of a multicenter double-blind placebo-controlled randomized trial;Terapevticheskii arkhiv;2023-12-22